ASX Stock

At Trader Dealer we understand the importance of information. You can use our handy company information finder to get key fundamental data about any company listed on the ASX.

Simply enter the stock code or the name of the company you are interested in for ASX share price information, company size, research analyst forecast, share and financial ratios, as well as a business and financial summary.

Don’t know the ASX code of the stock you want? Just click on the letter below for a full alphabetical listing.


Enter ASX Stock Code

Bookmark Page !



View all Companies by Letters

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z 


 
 

Clinuvel Pharmaceuticals Limited
Industry Group: Biotechnology - Biotechnology & Drugs

Trade Online with Trader Dealer

Sorry, No Chart Available.

Business Summary
Clinuvel Pharmaceuticals Limited (Clinuvel) is an Australia-based biopharmaceutical company developing its photoprotective pharmaceutical drug under the generic name afamelanotide. Afamelanotide is a man-made form of the protein which activates melanin, the skin’s natural defense against ultraviolet (UV) light. Clinuvel is testing the drug in five separate categories of patients, who suffer from light related skin disorders. The Company focuses on prophylactic treatment of Erythropoietic Porphyrias in clinical trials of afamelanotide. It also focused on preventing actinic keratosis and squamous cell carcinoma of the skin in organ transplant recipients in clinical trials of afamelanotide. Clinuvel is also focused on systemic Photo Dynamic Therapy (PDT) treatments. The Company’s wholly owned subsidiaries include A.C.N. 089 584 467 Pty Ltd, A.C.N. 108 768 896 Pty Ltd, Clinuvel (UK) Ltd, Clinuvel, Inc and Clinuvel AG.

Financial Summary
BRIEF: For the fiscal year ended 30 June 2010, Clinuvel Pharmaceuticals Limited's revenues decreased 36% to A$1.8M. Net loss decreased 25% to A$11.5M. Revenues reflect a decrease in interest income. Lower loss was offset by a decrease in depreciation & amortization expense, a fall in research & development cost and a decrease in operating lease expenses. The Company is engaged in biopharmaceutical business.

Business Address
Darren Keamy
CFO
Level 13 , 1 Collins Street
Melbourne, VIC 3000
Phone: 61-3-96604900
Fax: 61-3-96624999
http://www.clinuvel.com/

ASX Share Price Information
Current Price 0.230
Current Price Date 07/09/2010
52 Week Hi/Low 0.38 - 0.20
Avg Volume Last ten Days 0.13
ASX Company Sizing
Market Cap 69.73
Revenues 42.73
EBITDA -13.10
Net Income -11.52
Number of Employees 16
Enterprise Value 42.73
Research Analyst Forecast
Consensus Recommendation Outperform
Target Price 0.82000
LT Growth Rate -
Projected P/E -23.00000
Sales 12.38900
EPS -0.01000
Profit -2.90000
DPS 0.00000
Share Ratios
EPS -0.03800
RPS 0.00609
BV per Share 0.08716
Cash per Share 0.08906
Cashflow per Share -0.03564
Cashflow per Share 0.00000
Financial Ratios
Gross Margin -
ROE -36.29980
Price/Sales 37.78113
P/E -
P/Book 2.63883